TABLE 2
FROM:
Fertility, gonadal and sexual function in survivors of testicular cancer
R A Huddart, A Norman, C Moynihan, A Horwich, C Parker, E Nicholls and D P Dearnaley
BACK TO ARTICLETable 2. Disease and treatment characteristics of patients treated at The Royal Marsden Hospital between 1982 and 1992 entered into this study
| Chemotherapy | Chemotherapy/radiotherapy | Radiotherapy | Surveillance | Overall | |
|---|---|---|---|---|---|
| N | 272 | 81 | 158 | 169 | 680 |
| Histology | |||||
| Seminoma | 32 | 46 | 157 | 57 | 292 |
| NSGCT | 240 | 35 | 1 | 112 | 388 |
| a Chemotherapy regimes | |||||
| Platinum | 120 | 19 | 139 | ||
| BEP | |||||
| BOP | 35 | 3 | 38 | ||
| PVB | 12 | 14 | 26 | ||
| Other platinum regimes | 13 | 3 | 16 | ||
| Carboplatin | |||||
| Only | 18 | 33 | 51 | ||
| JEB | 74 | 7 | 87 | ||
| Other | 0 | 2 | 2 | ||
| Reason for radiotherapy | |||||
| Elective after chemotherapy | 61 | — | 61 | ||
| Stage I seminoma | 4 | 130 | 134 | ||
| Stage II seminoma | 12 | 27 | 39 | ||
| Stage I/II NSGCT | 4 | 1 | 5 | ||
NSGCT, nonseminomatous germ cell tumour.
a B, Bleomycin; E, Etoposide; P, Cisplatinum; J, Carboplatin; V, vinblastine; O, vincristine.
